

May 20, 2024

Jacquelyn Sumer
General Counsel
Cullinan Therapeutics, Inc.
One Main Street
Suite 1350
Cambridge, MA 02142

Therapeutics, Inc.
Statement on Form S-3

Re: Cullinan
Registration
Filed May 16, 2024
File No. 333-279452

Dear Jacquelyn Sumer:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sheppard at 202-551-8346 with any questions.

Please contact Tamika

Sincerely,

Division of Corporation Finance

Office of Life Sciences

cc:

Thomas Daniecki